Key Highlights

  • bioAffinity Technologies (NASDAQ:BIAF) rose 9.57% to USD 8.75 on October 8, 2026 in published market data on 5,095,395 shares, after announcing at 8:00 a.m. EDT a Japan Patent Office notice of allowance for its CyPath Lung algorithm.
  • The allowance covers an artificial intelligence built algorithm for detecting early-stage lung cancer in sputum using flow cytometry, and is the company's fifth Asian patent, among 22 granted and 36 pending.
  • A company release on October 6, 2026 said CyPath Lung sales rose more than 100% through the third quarter, with more than 1,620 tests delivered versus 775 and ordering physicians up 89%.
  • bioAffinity Technologies (NASDAQ:BIAF) held USD 2,429,719 of cash at June 30, 2026, versus USD 6,449,782 at year end 2025, after a first half net loss of USD 6,996,692.

What Was Announced

On October 8, 2026 the company said the Japan Patent Office issued a notice of allowance for a method covering its CyPath Lung test, which uses automated flow cytometry and Machine Learning to detect early-stage lung cancer in sputum. Issuance follows payment of a fee. A patent allowance protects intellectual property but is not revenue. The release on October 6 reported sales growth over 100% and a new distribution agreement with a veteran-owned firm. The patent news is the likely trigger of the move, but causation is inference. The stock gapped up 3.08% and climbed further after the open, which shows that buyers kept adding to the move after the bell, although Volume was far above normal and Liquidity is thin.

Financial and Listing Backdrop

In the second quarter of 2026, Revenue was USD 1,510,579, up 19%, with a net loss of USD 3,366,082, or USD 0.64 per share. First half revenue was USD 2,862,106, down from USD 3,123,080. The company raised about USD 3.2 million gross in a June 2026 offering and completed a 1-for-15 reverse split effective August 24, 2026, after a 1-for-30 split in September 2025. Nasdaq confirmed regained bid-price compliance on September 8, 2026, when 1,166,625 shares were outstanding. Because the company had a prior reverse split, it would not get a standard 180-day cure period if its bid price fell below USD 1.00 again, which raises the stakes for any share price decline.

Risks and What to Watch

Cash of USD 2.4 million is small against a half-year loss near USD 7.0 million, so more financing is likely, and each raise dilutes holders. The share count roughly doubled between late August and September 8, according to the filings, though the cause was not verified. Daily volume of about 5.1 million shares dwarfs the share count, a sign of speculative trading. The test is a laboratory developed product with a small revenue base. Investors in bioAffinity Technologies (NASDAQ:BIAF) should watch the third quarter report, probably in mid-November but unconfirmed, further financing and any Nasdaq notice. A patent allowance would not change that need for Capital by itself, and Japan approval of the test itself is a separate matter.

Where Things Stand

bioAffinity Technologies (NASDAQ:BIAF) jumped 9.6% most likely because of the Japan patent allowance and recent sales growth news, though causation is inferred. The allowance adds protection for CyPath Lung but no revenue, and the company holds only USD 2.4 million of cash after two reverse splits in 12 months. The balance of evidence is promising technology with heavy financing and listing risk. The next catalysts are the third quarter report and any new financing.